- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01363115
Calcium Supplementation for a Healthy Weight (CaSHeW) (CaSHeW)
Study Overview
Status
Conditions
Detailed Description
The prevalence of obesity and levels of overweight is rising worldwide. In the United States, 63% of men and 55% of women are now overweight or obese. Recent epidemiological data and clinical trials have shown that a small daily increase in calcium or dairy products may result in annual losses in body weight and body fat. Data from clinical studies suggest that a 1000 mg per day increase in calcium intake is associated with an 8 kg difference in mean body weight and that calcium intake explains about 3% of the variance in body weight.
The objective of this study is to investigate the effect of calcium (Ca) and vitamin D (D) supplemented orange juice (OJ) on weight loss and visceral fat mass in overweight and obese adults.
Otherwise healthy overweight and obese men and women ages 18 to 65 years with a BMI between 25 and 35 kg/m2 will be randomized into one of the following experimental groups (36 in each group):
- Regular OJ: one 8 fluid oz serving three times/day (control)
- Regular OJ fortified with Calcium (350 mg/8 fluid oz serving) and Vitamin D3 (100 IU/8 fluid oz serving): one 8 fluid oz serving three times/day (treatment)
Subjects will receive either orange juice (OJ) (control) or OJ fortified with calcium and vitamin D3 (treatment) for 16 weeks. The study will involve 6 outpatient study visits to the study center.
Primary endpoint: Change in body weight after 16 weeks Secondary endpoint: Visceral fat change after 16 weeks as measured by single slice CT scan
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital Weight Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women, between 18 and 65 years of age, who are capable of providing informed consent.
- BMI of 25 to 35 kg/m2
- Non-smoker (for at least 6 months).
- In good health, as determined by the principal investigator based on medical history and physical examination.
- Clinical laboratory evaluations (including Biochemistry, Hematology, Urinalysis) within the reference range for the test laboratory, unless deemed not clinically significant by the Investigator.
- Because of the calorie-restricted diet and radiation exposure from the CT scan, females will be non-pregnant, non-lactating, and either post-menopausal for at least 1 year, surgically sterile for at least 3 months, or be willing to use an approved method of contraception (which may include use of abstinence; non-hormonal intrauterine device with spermicide; female condom with spermicide; diaphragm with spermicide; cervical cap with spermicide; oral or transdermal hormonal contraceptives; a condom with spermicide by the sexual partner; or a sterile sexual partner) from 35 days prior to study entry (i.e., Day -1) until 30 days following Study Completion. For all females, the pregnancy test result must be negative at the screening visit and at visits when a CT scan will be done.
- Ability to comprehend and willingness to sign the Informed Consent Form for this study.
- Ability to comply with study restrictions regarding diet and exercise
- Stable weight (+ 5%) for at least 3 months prior to study entry.
Exclusion Criteria:
- Diabetes mellitus
- History or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders which in the opinion of the investigator would be expected to interfere with the study or increase risk to the subject.
- Participation in any other investigational diet study within 90 days prior to study entry.
- History of a medical or psychological condition or social circumstances that would impair the subject's ability to participate reliably in the study.
- Use within the last six months of medications that can result in significant weight gain or weight loss, including antipsychotics, selective serotonin reuptake inhibitors, anti-epileptic drugs, appetite-suppressants such as phentermine and sibutramine, and the lipase-inhibitor orlistat.
- Active eating disorder
- History of alcoholism or substance abuse within 5 years prior to study entry.
- Use of a dietary supplement or medication that decreases calcium absorption
- History of kidney stone, hyperparathyroidism or sarcoidosis
- High calcium intake (more than 2 servings of dairy products per day or taking calcium supplements > 3x/wk ) for 1 month prior to study start date and for duration of study. (If participant is taking calcium supplement > 3x/wk or more than 2 servings of dairy products per day, they are eligible to participate if they agree to stop for 1 month prior to study start date and for the duration of the study. Participants will similarly be asked to stop multivitamins as the majority of these supplements contain calcium.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: OJ fortified with Ca and VitD
Regular OJ fortified with Calcium (350 mg/8 fluid oz serving) and Vitamin D3 (100 IU/8 fluid oz serving): one 8 fluid oz serving three times/day (treatment) in combination with nutritional counseling
|
Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
Other Names:
Individual and group nutritional counseling by a registered dietitian
|
|
Active Comparator: OJ without VitD and Ca
Regular OJ without Calcium or Vitamin D3: one 8 fluid oz serving three times/day (control)
|
Individual and group nutritional counseling by a registered dietitian
Three 240 mL glasses of orange juice without Ca or VitD
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in body weight
Time Frame: Baseline and 16 weeks
|
Baseline and 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in visceral adipose tissue mass
Time Frame: Baseline and 16 weeks
|
Baseline and 16 weeks
|
|
Change in subcutaneous adipose tissue mass
Time Frame: Baseline and 16 weeks
|
Baseline and 16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lee M Kaplan, MD, PhD, Massachusetts General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2005-P-000414
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
Clinical Trials on Orange Juice fortified with Calcium and Vitamin D
-
National Nutrition and Food Technology InstituteCompletedHealthy | Vitamin D Status
-
Massachusetts General HospitalThe Beverage Institute for Health and WellnessCompleted
-
Agricultural University of AthensCompletedHypertension | Dyslipidemias | Overweight and Obesity | PrediabetesGreece
-
Boston UniversityCompleted
-
Hasselt UniversityHochschule Geisenheim UniversityCompleted
-
University of TorontoNatural Ovens of Manitowoc, Manitowoc, USACompletedVitamin D Deficiency | Low Bone Density
-
Universiti Putra MalaysiaCompleted
-
Agricultural University of AthensCompletedAcute Effects of Juice Consumption With Biofunctional Compounds and Probiotics on Glucose MetabolismAppetite Disorders | Potential Abnormality of Glucose ToleranceGreece
-
University of HohenheimCompleted
-
University of Nevada, RenoUnited States Department of Agriculture (USDA); Sierra Nevada Nephrology Consultants...CompletedHyperkalemia | Chronic Kidney Disease Requiring Chronic DialysisUnited States